主动监测中首次随访活检阴性可降低疾病升级与转为积极治疗的风险
该研究纳入2003至2018年伦敦某三级医院460例接受主动监测的低中危前列腺癌患者,评估首次随访活检阴性后的疾病进展与治疗转换风险。中位随访62个月,首次随访活检阴性者转为积极治疗、怀疑疾病进展及病理升级的风险均显著降低,提示对此类患者可考虑降低监测强度。
要点
- 首次随访活检阴性者转为积极治疗风险显著降低(HR 0.18)。
- 首次随访活检阴性者怀疑疾病进展风险降低(HR 0.56)。
- 首次随访活检阴性者病理升级风险降低(HR 0.48)。
核心结论
- 主动监测前列腺癌患者首次随访活检阴性,与后续升级、怀疑进展及转为积极治疗风险降低强烈相关。
- 对此类患者应考虑降低监测强度。
研究设计与样本
- 单中心回顾性队列研究,纳入2003至2018年伦敦某三级医院460例接受主动监测的低中危前列腺癌患者。
- 纳入标准为Gleason分级分组<3、临床分期<T3、诊断时PSA<20 ng/mL。
- 活检方式包括经直肠超声引导(12-14针)或经会阴(中位32针)活检。
主要发现
- 460例 eligible 患者中23%首次随访活检阴性,中位随访62个月。
- 首次随访活检阴性者转为积极治疗风险降低(HR 0.18,95%CI 0.09-0.37;P<0.001)。
- 首次随访活检阴性者怀疑疾病进展风险降低(HR 0.56,95%CI 0.34-0.94;P=0.029)。
- 首次随访活检阴性者病理升级风险降低(HR 0.48,95%CI 0.23-0.99;P=0.047)。
关键数值与推荐
- 怀疑疾病进展定义为活检升级、阳性针数>30%、MRI Likert评分>3/T3或PSA>20 ng/mL。
- 转为积极治疗包括根治性治疗或激素治疗。
临床怎么用
- 对主动监测中首次随访活检阴性的前列腺癌患者,可考虑降低监测强度。
局限性
- 接受多次随访活检的男性较少,数据受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance (AS) for prostate cancer (PCa). PATIENTS AND METHODS: Men on an AS programme at a single tertiary hospital (London, UK) between 2003 and 2018 with confirmed low-intermediate-risk PCa, Gleason Grade Group <3, clinical stage <T3 and a diagnostic prostate-specific antigen (PSA) level of <20 ng/mL. This cohort included men diagnosed by transrectal ultrasonography guided (12-14 cores) or transperineal (median 32 cores) biopsy. Multivariate Cox hazards regression analysis was undertaken to determine (i) risk of upgrading, (ii) clinical or radiological suspicion of disease progression, and (iii) transitioning to active treatment. Suspicion of disease progression was defined as any biopsy upgrading, >30% positive cores, magnetic resonance imaging (MRI) Likert score >3/T3 or PSA level of >20 ng/mL. Conversion to treatment included radical or hormonal treatment. RESULTS: Among the 460 eligible patients, 23% had negative follow-up biopsy findings. The median follow-up was 62 months, with one to two repeat biopsies and two MRIs per patient during that period. Negative biopsy findings at first repeat biopsy were associated with decreased risk of converting to active treatment (hazard ration [HR] 0.18, 95% confidence interval [CI] 0.09-0.37; P < 0.001), suspicion of disease progression (HR 0.56, 95% CI: 0.34-0.94; P = 0.029), and upgrading (HR 0.48, 95% CI 0.23-0.99; P = 0.047). Data are limited by fewer men with multiple follow-up biopsies. CONCLUSION: A negative biopsy finding at the first scheduled follow-up biopsy among men on AS for PCa was strongly associated with decreased risk of subsequent upgrading, clinical or radiological suspicion of disease progression, and conversion to active treatment. A less intense surveillance protocol should be considered for this cohort of patients.
引用
- Singh S, Sandhu P, Beckmann K, et al. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment. BJU Int. 2020. PMID: 33098158. doi:10.1111/bju.15281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。